tiprankstipranks
Advertisement
Advertisement

OCUL Stock Latest News

OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
Company AnnouncementsOCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
19d ago
OCUL
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
19d ago
P
CW
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
PremiumThe Fly
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
1M ago
OCUL
Ocular Therapeutix price target raised to $30 from $24 at Baird
PremiumThe Fly
Ocular Therapeutix price target raised to $30 from $24 at Baird
1M ago
OCUL
Ocular Therapeutix trading resumes
PremiumThe Fly
Ocular Therapeutix trading resumes
1M ago
OCUL
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
PremiumThe FlyOcular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
1M ago
OCUL
Ocular Therapeutix to resume trading at 9:15 am ET
Premium
The Fly
Ocular Therapeutix to resume trading at 9:15 am ET
1M ago
OCUL
Ocular Therapeutix trading halted, news pending
Premium
The Fly
Ocular Therapeutix trading halted, news pending
1M ago
OCUL
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
PremiumCompany Announcements
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
1M ago
8K
OCUL
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
PremiumCompany Announcements
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
3M ago
OCUL
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
PremiumRatings
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
3M ago
OCUL
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
PremiumRatings
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
3M ago
OCUL
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
PremiumRatingsAnalyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
3M ago
OCUL
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
Premium
The Fly
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
3M ago
OCUL
Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Ocular Therapeutix Inc (OCUL) Q1 Earnings Cheat Sheet
3M ago
OCUL
Ocular Therapeutix enrolls first patient in Axpali trial
PremiumThe Fly
Ocular Therapeutix enrolls first patient in Axpali trial
3M ago
OCUL
Ocular Therapeutix reports additional Axpaxli trial data
PremiumThe Fly
Ocular Therapeutix reports additional Axpaxli trial data
3M ago
OCUL
Ocular Therapeutix price target raised to $27 from $24 at BofA
PremiumThe Fly
Ocular Therapeutix price target raised to $27 from $24 at BofA
5M ago
OCUL
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
PremiumRatings
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
5M ago
OCUL
Ocular Therapeutix price target raised to $28 from $21 at Clear Street
PremiumThe FlyOcular Therapeutix price target raised to $28 from $21 at Clear Street
5M ago
OCUL
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
Premium
Ratings
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
5M ago
OCUL
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
Premium
Ratings
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
5M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >